X0202 SCHEDULE 13D/A 0001232258 XXXXXXXX LIVE 1 Ordinary shares, no par value per share 09/07/2026 false 0001534248 16385C203 Chemomab Therapeutics Ltd.

KIRYAT ATIDIM, BUILDING 7 Tel Aviv L3 ISRAEL

Jean-Marc LeSieur 1345 946 8002 Governors Square 23 Lime Tree Bay Avenue, PO Box 30852 Grand Cayman E9 KY1-1204 0001232258 N HBM Healthcare Investments (Cayman) Ltd. WC N E9 80971680.00 0.00 80971680.00 0.00 80971680.00 N 12.5 CO The amount of shares reported in rows 7, 9 and 11 reflect the number of Ordinary Shares (as defined herein) represented by the ADSs (as defined herein) that the Reporting Person owns. Voting and investment power over the Ordinary Shares represented by the ADSs held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the "Board"). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the Ordinary Shares represented by ADSs. Ordinary shares, no par value per share Chemomab Therapeutics Ltd. KIRYAT ATIDIM, BUILDING 7 Tel Aviv L3 ISRAEL Pursuant to Rule 13d-2 under the Act, this Amendment No. 1 to the Schedule 13D ("Amendment No. 1") amends certain items of the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 16, 2026 (the "Original Schedule 13D" and, together with this Amendment No. 1, the "Schedule 13D"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. HBM Healthcare Investments (Cayman) Ltd. (the "Reporting Person" or "HBM") owns American Depositary Shares ("ADSs") of the Issuer. Each one ADS represents eighty (80) ordinary shares, no par value per share, of the Issuer ("Ordinary Shares"). The Ordinary Shares are registered under Section 12 of the Act, and the ADSs are not deemed a separate class of securities for purposes of calculating beneficial ownership under Section 13(d) of the Act. Accordingly, the Reporting Person's beneficial ownership is reported in this Schedule 13D in terms of Ordinary Shares, not ADSs. However, the CUSIP provided in this statement is the CUSIP for the Issuer's ADSs, because there is no CUSIP number assigned to the Ordinary Shares. Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On September 7, 2026, HBM sent formal notice to the Issuer of its election to exercise its Pre-Funded Warrants in order to effectuate its voting obligations under the Shareholder Support Agreement (as defined and described in the Original Schedule 13D). HBM Healthcare Investments (Cayman) Ltd. /s/ Jean-Marc LeSieur 09/09/2026